期刊文献+

前蛋白转化酶枯草溶菌素9在绝经前后女性中的差异 被引量:2

Difference in proprotein convertase subtilisin/kexin type 9 levels between premenopausal and postmenopausal women
原文传递
导出
摘要 目的探讨前蛋白转化酶枯草溶菌素9(PCSK9)在绝经前和绝经后女性中的差异及其与代谢因素的相关性。方法从2009年参加南京2型糖尿病预测、预防、干预研究调查人群中随机抽取515名女性,收集空腹血样本,并对人选者进行问卷调查、体格检查及代谢相关指标的测定,用酶联免疫吸附法检测血清PCSK9水平。结果在女性人群中血清PCSK9水平与低密度脂蛋白胆固醇(LDL—C)、总胆固醇(TC)、甘油三酯、空腹血糖、体重指数、腰臀比、年龄呈正相关(均P〈0.01),绝经前女性的PCSK9水平显著低于绝经后的女性[(58.18±25.44对80.91±33.74)ng/ml,P〈0.01]。结论绝经前女性的PCSK9水平低于绝经后女性,且PCSK9水平与年龄、TC、LDL—C密切相关。 Objective To compare proprotein convertase subtilisin/kexin type 9 (PCSK9) levels between premenopausal and postmenopausal women, and to investigate the relationship between serum PCSK9 and metabolic factors. Methods Totally 515 women were enrolled from the study on diabetes of prediction, prevention, and intervention in Nanjing in 2009. Survey, physical examinations, and determination of related metabolic indexes were performed. Serum PCSK9 level was measured by sandwich ELISA. Results Serum PCSK9 level was positively correlated with low density lipoprotein-cholesterol ( LDL-C ), total cholesterol ( TC ), triglyceride, fasting plasma glucose, body mass index, waist-hip ratio, and age in women ( all P〈0.01 ). PCSK9 level was significantly lower in premenopausal women than that in postmenopausal women [ ( 58. 18 ±25. 44 vs 80. 91 ± 33. 74 ) ng/ml, P 〈 0.01 ]. Conclusion Higher level of PCSK9 exists in postmenopausal women compared with premenopausal women. The level of PCSK9 is closely correlated with age, TC, and LDL-C.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2013年第1期46-49,共4页 Chinese Journal of Endocrinology and Metabolism
基金 国家自然科学基金资助项目(81170747):江苏省六大人才高峰(2008-18D)
关键词 前蛋白转化酶枯草溶菌素9 低密度脂蛋白胆固醇 绝经 Proprotein convertase subtilisin/kexin type 9 Low density lipoprotein-cholesterol Menopausal
  • 相关文献

参考文献21

  • 1Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9 : a regulator of plasma LDL-cholesterol. Structure, 2007,15 : 545-552.
  • 2Lalanne F, Lambert G, Amar M J, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res, 2005,46:1312-1319.
  • 3Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) : hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology, 2008,48:646-654.
  • 4Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin/kexin type 9 is correlated directly with serum LDL cholesterol. J Clin Chcm, 2007,53:1814-1819.
  • 5HollaoL, Laerdahl JK, strom TB, et al. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor. Biochem Biophys Res Commun, 2011,406:234-238.
  • 6Yamamoto T, Lu C, Ryan RO. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem, 2011,286:5464-5470.
  • 7Jeong H J, Lee HS, Kim KS, et al. Sterol-depeudent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol- regulatory element binding protein-2. J Lipid Res, 2008,49:399-409.
  • 8Palacios L, Grandoso L, Cuevas N, et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis, 2011,221: 137-142.
  • 9Cohen JC, Boerwinkle E, Mosley Jr TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006,354 : 1264-1272.
  • 10Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasnm PCSK9 levels. J Clin Endocrinol Metab, 2009, 94 : 2537-2543.

同被引文献39

  • 1吴娜琼.2011美国国家脂质协会成人家族性高胆固醇血症患者管理建议解读[J].中国医学前沿杂志(电子版),2012,4(2):48-54. 被引量:4
  • 2Kosenko T,Golder M,Leblond G,et al.Low density lipoproteinbinds to proprotein convertase subtilisin/kexin type-9(PCSK9) in human plasma and inhibits PCSK9- mediated low density lipoprotein re-ceptor degradation[J].J Biol Chem,2013,288(12):8279-8288.
  • 3Desai,N.R, Giugliano,R.P, Zhou,J.et al.AMG 145,a monoclonal antibody against PCSK9,facilitates achievement of national cholesterol education program-adult treatment panel III lowdensity lipoprotein cholesterol goals among high-risk patients: An analysis from the LAPLACE-TIMI 57 trial(LDL-C assessment with PCSK9 monoclonaL antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)[J].Journal of the American College of Cardiology,2014,63(5):430-433.
  • 4Luna Saavedra YG,Zhang J,Seidah NG. PCSK9 prosegment chimera as novel inhibitors of LDL R degradation[J].PLoS One,2013,8(8): 113.
  • 5Seidah N G,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC- 1):liver regeneration and neuronal differentiation[J].Proe Natl Acad Sci U S A,2003,100(3):928-933.
  • 6Zaid A,Roubtsova A,Essalmani R,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9):hepatocytespecific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration[J]. Hepatology,2008,48(2):646-654.
  • 7Grozdanov PN,Petkov PM,Karagyozov LK,Dabeva MD.Expression and localization of PCSK9 in rat hepatic cells.Biochem Cell Biol.2006 Feb,84(1):80-92.
  • 8Butkinaree C,Canuel M,Essalmani R,et al.Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertase-mediated low density lipoprotein receptor degradation but interact with each other[J].Biol Chem,2015,17:180.
  • 9Poirier S,Prat A,Marcinkiewicz E,et al.Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system[J].Neurochem,2006,98(3):838.
  • 10Lambert G,Charlton F, Rye K A,et al. Molecular basis of PCSK9 function[J].Atherosclerosis,2009,203(1): 1-7.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部